Summary

Classifying patients with uncontrolled hypertension by degree of response to valsartan monotherapy has a limited value in predicting which patients will benefit from the addition of hydrochlorothiazide (HCTZ), according to findings from a new study. Despite failing to meet blood pressure (BP) targets with valsartan monotherapy, all patients with stage 2 hypertension experienced dose-dependent improvements in BP control with the addition of HCTZ.